METTL3 and esophageal squamous cell carcinoma: The authors also showed that the HIV drug elvitegravirpromotes METTL3 degradation (see the Elvitegravir:A METTL3 Degrader section) and in turn suppresses ESCC metastasisboth in vitro and in vivo.